Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


The Fertility Show


 

Aggressive brain cancer linked to gene fusion

30 July 2012

By Dr Zara Mahmoud

Appeared in BioNews 667

Some cases of glioblastoma - a particularly aggressive form of brain cancer - may be due a genetic mutation where two separate genes fuse into one, scientists report.

In research published in the journal Science, blocking the activity of the protein produced by this mutation slowed down the progression of the disease in mice.

The study, led by Professor Antonio Iavarone at Columbia University in New York, USA, began with detailed genetic analysis of cells from nine glioblastoma patients. After identifying mutations that the researchers suspected might be involved in the disease, they extended their analysis to another 97 samples from glioblastoma patients registered with the Cancer Genome Atlas project (see story in BioNews 666).

In 3% (percent) of the glioblastoma cases studied, the gene fusion mutation was implicated. Under normal conditions, the two genes produce separate proteins that ensure even distribution of chromosomes in the two daughter cells resulting from cell division, or mitosis.

The gene product of the fused genes takes on this function but performs it in unusual places or contexts; the proteins 'do their thing, but incorrectly', co-lead author Dr Anna Lasorella told New Scientist. As a result, the mutation causes uneven distribution of the chromosomes in the daughter cells. This is called aneuploidy, and is a hallmark of cancer cells.

Professor Iavarone called his team's findings 'doubly important. From a clinical perspective, we have identified a druggable target for a brain cancer with a particularly dismal outcome. From a basic research perspective, we have found the first example of a tumour-initiating mutation that directly affects how cells divide, causing chromosomal instability'.

In their study, the scientists also introduced the mutation into healthy mice and over 90% developed an aggressive brain tumour. Administration of drugs inhibiting the protein's activity slowed progression of the disease and came close to doubling the life-span of the mice with cancer.

Professor Stephen Emerson, director of the Herbert Irving Comprehensive Cancer Centre at Columbia University Medical Centre said the study was 'perhaps a first step toward a personalised, precision approach to the treatment of glioblastoma'.

Speaking to the Press Association for Cancer Research UK, Peter Collins, professor of neuroscience at the University of Cambridge, who was not involved in the study, commented: 'With more and more of these "next-generation" gene sequencing projects reporting over the coming years, more drug targets will be identified'.

SOURCES & REFERENCES
New Scientist | 26 July 2012
 
Cancer Research UK | 26 July 2012
 
Science Daily | 26 July 2012
 
Wall Street Journal | 26 July 2012
 
Science | 26 July 2012
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

31 July 2017 - by Rikita Patel 
The IBM Watson supercomputer can analyse 160 hours' worth of genomic data in just ten minutes...
04 March 2013 - by Reuben Harwood 
Losing genes that help stabilise a cells DNA may explain why some cancers are resistant to treatment, say scientists...
28 January 2013 - by Reuben Harwood 
Nearly all cases of meningioma – the commonest kind of brain tumour – can be traced back to a fault in one of just five genes, scientists say...
22 October 2012 - by Joseph Jebelli 
A study on the most common type of brain cancer in humans has found that expressing cancer genes, also known as oncogenes, in fully developed brain cells can return them to an immature state that results in the formation of tumours...
24 September 2012 - by Dr Lux Fatimathas 
The first detailed maps of genetic activity in the human brain have been published online by scientists...

28 May 2012 - by James Brooks 
A drug that mimics broken strands of DNA and pushes treatment-resistant cancer cells to autodestruct has produced encouraging results in a first clinical trial. The medicine, DT01, is the forerunner for a new class of drug developed by researchers at the Institut Curie in Paris...
15 May 2012 - by Dr Lux Fatimathas 
Scientists have discovered the enzyme in our cells which corrects the most frequently occurring mistake in DNA as cells divide...
05 December 2011 - by Sarah Pritchard 
Two gene rearrangements associated with prostate and lung cancer could also be behind five to seven percent of all breast cancers, according to US scientists...
14 February 2011 - by Victoria Kay 
A genetic screening test could help doctors to identify men with the most aggressive types of prostate cancer, UK scientists believe. The test could save men with milder forms of the disease from unnecessary surgery and its potentially serious side effects...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Moving the Boundaries of Human Reproduction

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Jacques Cohen

Dr Anna Smajdor

Dr Andy Greenfield

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation